Sasson AN, Ingram RJM, Zhang Z, Taylor LM, Ananthakrishnan AN, Kaplan GG, et al
The American Heart Association recognizes GLP-1 receptor agonists as beneficial for people with obesity and heart disease
( Epub 2015/05/20 )
RAD51-dependent recruitment of TERRA lncRNA to telomeres through R-loops
With the rise of counterfeit drugs and compounding concerns, Debussy emphasized the importance of consulting medical professionals
Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members